Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 7 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
QuidelOrtho has 11 pending office actions in Biotechnology & Pharmaceuticals. The matters span 11 distinct examiners and 7 distinct art units, indicating a broad and distributed prosecution workload. LU, FRANK WEI MIN is the busiest examiner, with 1 pending matter.
The examiner count matches the number of pending actions, so counsel should expect application-specific prosecution rather than a single consolidated examiner relationship. The smaller art-unit figure indicates some technical grouping across the docket, which may support comparison of recurring examination themes. A centralized claim vocabulary and disclosure map can help preserve portfolio consistency while allowing responses to reflect each examiner’s distinct record.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 3 (27%) |
| §101 + other | 4 (36%) |
| §112 only | 1 (9%) |
| Double-patenting only | 2 (18%) |
| Double-patenting + other | 1 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LU, FRANK WEI MIN | 1 | 62.7% | +67.9% |
| SCHULTZHAUS, JANNA NICOLE | 1 | 35.4% | +38.2% |
| LIN, JERRY | 1 | 72.2% | +14.8% |
| BAILEY, STEVEN WILLIAM | 1 | 31.6% | +15.2% |
| BUNKER, AMY M | 1 | 29.1% | +45.6% |
| LEVERETT, MARY CHANG | 1 | 59.4% | +23.5% |
| PLAYER, ROBERT AUSTIN | 1 | 13.6% | +34.1% |
| KALLAL, ROBERT JAMES | 1 | 59.4% | +31.2% |
| CLOW, LORI A | 1 | 64.2% | +28.5% |
| VANNI, GEORGE STEVEN | 1 | 66.8% | +25.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17691999 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | CLOW, LORI A | 23d overdue |
| 18195763 | METHODS FOR NON-INVASIVE ASSESSMENT OF FETAL GENETIC VARIATIONS THAT FACTOR EXPERIMENTAL CONDITIONS | BUNKER, AMY M | 7d |
| 18429893 | METHODS FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SCHULTZHAUS, JANNA NICOLE | — |
| 18459747 | Methods and Processes for Non-Invasive Assessment of Genetic Variations | LIN, JERRY | — |
| 18317573 | Methods and Processes for Assessment of Genetic Variations | BAILEY, STEVEN WILLIAM | — |
| 18080620 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | LEVERETT, MARY CHANG | — |
| 18045279 | Methods for Non-Invasive Assessment of Genomic Instability | PLAYER, ROBERT AUSTIN | — |
| 17773671 | APPLICATION OF MOSAICISM RATIO IN MULTIFETAL GESTATIONS AND PERSONALIZED RISK ASSESSMENT | KALLAL, ROBERT JAMES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17691999 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | CLOW, LORI A | 23d overdue |
| 18195763 | METHODS FOR NON-INVASIVE ASSESSMENT OF FETAL GENETIC VARIATIONS THAT FACTOR EXPERIMENTAL CONDITIONS | BUNKER, AMY M | 7d |
| 18800497 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | LU, FRANK WEI MIN | 72d |
| 18429893 | METHODS FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SCHULTZHAUS, JANNA NICOLE | — |
| 18459747 | Methods and Processes for Non-Invasive Assessment of Genetic Variations | LIN, JERRY | — |
| 18317573 | Methods and Processes for Assessment of Genetic Variations | BAILEY, STEVEN WILLIAM | — |
| 18080620 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | LEVERETT, MARY CHANG | — |
| 18045279 | Methods for Non-Invasive Assessment of Genomic Instability | PLAYER, ROBERT AUSTIN | — |
| Art Unit | Apps |
|---|---|
| 1685 | 4 |
| 1687 | 2 |
| 1683 | 1 |
| 1684 | 1 |
| 2857 | 1 |
| 1672 | 1 |
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18800497 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | LU, FRANK WEI MIN | 1683 | §112 | Non-Final OA | 72d | Pending | Aug 12, 2024 |
| 18429893 | METHODS FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SCHULTZHAUS, JANNA NICOLE | 1685 | §101Other | Final Rejection | — | Pending | Feb 01, 2024 |
| 18459747 | Methods and Processes for Non-Invasive Assessment of Genetic Variations | LIN, JERRY | 1685 | §101§102§112DP | Non-Final OA | — | Pending | Sep 01, 2023 |
| 18317573 | Methods and Processes for Assessment of Genetic Variations | BAILEY, STEVEN WILLIAM | 1687 | §101§102§112DP | Non-Final OA | — | Pending | May 15, 2023 |
| 18195763 | METHODS FOR NON-INVASIVE ASSESSMENT OF FETAL GENETIC VARIATIONS THAT FACTOR EXPERIMENTAL CONDITIONS | BUNKER, AMY M | 1684 | DP | Final Rejection | 7d | Pending | May 10, 2023 |
| 18080620 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | LEVERETT, MARY CHANG | 2857 | §101DP | Non-Final OA | — | Pending | Dec 13, 2022 |
| 18045279 | Methods for Non-Invasive Assessment of Genomic Instability | PLAYER, ROBERT AUSTIN | 1672 | §101§103§112DP | Non-Final OA | — | Pending | Oct 10, 2022 |
| 17773671 | APPLICATION OF MOSAICISM RATIO IN MULTIFETAL GESTATIONS AND PERSONALIZED RISK ASSESSMENT | KALLAL, ROBERT JAMES | 1685 | §101 | Non-Final OA | — | Pending | May 02, 2022 |
| 17691999 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | CLOW, LORI A | 1687 | §101 | Final Rejection | 23d overdue | Pending | Mar 10, 2022 |
| 17427002 | COMPOSITIONS, METHODS, AND SYSTEMS TO DETECT HEMATOPOIETIC STEM CELL TRANSPLANTATION STATUS | VANNI, GEORGE STEVEN | 1686 | §112DP | Non-Final OA | — | Pending | Jul 29, 2021 |
| 17140426 | Methods and Processes for Non-Invasive Assessment of Genetic Variations | ROSSI, VY BUI | 1685 | DP | Final Rejection | — | Pending | Jan 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQuidelOrtho has 11 pending office actions as of October 2026, spread across 7 art units and 11 examiners.
Frank Wei Min Lu has the most, with 1 of QuidelOrtho's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
